Windtree Therapeutics (NASDAQ:WINT) stock is surging today after the biotechnology company shared an update on its clinical trial of istaroxime. The Phase 2 SEISMiC Extension Study, which is testing istaroxime on SCAI Stage B early cardiogenic shock patients, is expected to complete enrollment in the coming weeks. Topline data from this study is anticipated by the end of the quarter, paving the way for a Phase 3 clinical trial. Windtree Therapeutics is also preparing to study istaroxime for the treatment of SCAI Stage C cardiogenic shock patients, a more severe group than those in Stage B.
Chairman and CEO Craig Fraser expressed satisfaction with the progress in clinical development, highlighting the importance of addressing the unmet needs of the patient populations under study.
WINT Stock Movement on Friday
Following this news, WINT stock has seen heavy trading activity, with over 5 million shares exchanging hands, significantly higher than its daily average volume. The stock has surged by 116% as of Friday morning.
Stay tuned for more updates on the latest stock market news today, including pre-market movers and recent developments.
Analysis:
Windtree Therapeutics is making significant strides in its clinical development efforts with the promising results of its Phase 2 SEISMiC Extension Study. The potential success of istaroxime in treating cardiogenic shock patients could have a substantial impact on the company’s future prospects and stock performance. Investors should closely monitor further developments and upcoming data releases to gauge the potential market impact and investment opportunities in Windtree Therapeutics.